Buradasınız

Hipotansiyon, Kronik Böbrek Yetmezlikli Hastada Mirtazapinin Etkisi

Hypotension, the Infl uence of Mirtazapine in a Patient with Chronic Renal Failure

Journal Name:

Publication Year:

DOI: 
10.5262/tndt.2013.1003.13
Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In patients with end-stage renal disease (ESRD), depression is the most commonly identifi ed psychiatric illness; however, its prevalence varies since it is assessed by using different methods in different studies and in different populations. The commonly accepted view in the treatment of depression is a combination of psychotherapy and pharmacologic treatment. Mirtazapine is an antidepressant used in the treatment of major depressive illness which affects both noradrenergic and serotonergic activity. This paper is a case report of a 40 year old man with a history of renal failure who developed hypotension while receiving mirtazapine therapy. We believe that hypotension was a conclusion of the mirtazapine in our patient and hemodialysis had no infl uence on hypotension. Hypotension improved after the metabolization of mirtazapine (approximately thirty-six hours).
Abstract (Original Language): 
Son dönem böbrek yetmezliği olan hastalarda depresyon en sık tanımlanan psikiyatrik hastalıktır, fakat depresyon prevalansı farklı çalışmalarda, farklı popülasyonlarda, farklı yöntemlerle değerlendirildiğinden değişiklikler göstermektedir. Depresyon tedavisinde kabul gören genel görüş tedavide psikoterapi ve ilaç tedavisinin kombinasyonu şeklindedir. Mirtazapin hem noradrenerjik hem de serotonerjik aktiviteyi etkileyen ve majör depresyon ile duygu durum hastalıklarında kullanılan anti depresan ilaçtır. Bu makalede, 40 yaşında böbrek yetmezliği öyküsü olan erkek hastada mirtazapin tedavisi sırasında gelişen hipotansiyon sunulmuştur. Düşüncemize göre, hipotansiyon mirtazapin kullanımın bir sonucu oluşmuştur ve hipotansiyon üzerine diyalizin bir etkisi yoktur. İlaç metabolize edildikten sonra hipotansiyon düzelmiştir (Yaklaşık 36. saat).
307
309

REFERENCES

References: 

1. Kimmel PL, Cukor D, Cohen SD, Peterson RA: Depression in endstage
renal disease patients: A critical review. Advances in Chronic
Kidney Disease 2007; 14 (4): Pages 328-334
2. Hedayati SS, Yalamanchili V, Finkelstein FO: A practical approach
to the treatment of depression in patients with chronic kidney
disease and end-stage renal disease. Kidney International 2012; 81:
247-255
3. Fraile P, Garcia-Cosmes P, Garcia T, Corbacho L, Alvarez M,
Tabernero JM: Hypotension, as consequence of the interaction
between tacrolimus and mirtazapine, in a patient with renal
transplant. Nephrol Dial Transplant 2009; 24(6): 1999-2001
4. Cohen SD, Norris L, Acquaviva K, Peterson RA, Kimmel PL:
Screening, Diagnosis, and Treatment of Depression in Patients with
End-Stage Renal Disease. CJASN 2007; 2 (6): 1332-13425. Timmer CJ, Sitsen JM, Delbressine LP: Clinical pharmacokinetics
of mirtazapine. Clin Pharmacokinet 2000; 38(6): 461-474
6. Frazer A: Pharmacology of antidepressants. J Clin Psychopharmacol
1997; 17: 2S-18S
7. Stimmel GL, Sussman N, Wingard P: Mirtazapine safety and
tolerability: Analysis of the clinical trials database. Primary
Psychiatry 1997; 1: 82-96
8. Bengtsson F, Höglund P, Timmer C, Hegbrant J: Mirtazapine oral
single dose kinetics in patients with different degrees of renal
failure. Human Psychopharmacology: Clinical and Experimental
1998; 13(5): 357-365
9. Störmer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism
of the antidepressant mirtazapine in vitro: Contribution of
cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000;
28(10): 1168-1175
10. Yalcin AU, Kudaiberdieva G, Sahin G, Gorenek B, Akcar N,
Kuskus S, Bayrak F, Timuralp B: Effect of sertraline hydrochloride
on cardiac autonomic dysfunction in patients with hemodialysisinduced
hypotension. Nephron Physiol 2003; 93(1): P21-28

Thank you for copying data from http://www.arastirmax.com